Defence Therapeutics, a biotech company focused on precision oncology, is progressing its Accum®-enhanced antibody-drug conjugate partnerships and radiotherapeutics programs under new CEO Dr. Amie Phinney. The company strengthened its scientific advisory board and leadership team to support its strategy, including performance-based stock incentives tied to share price milestones. Defence also received a second settlement payment related to a sharing agreement, maintaining focus on advancing its drug delivery platform and exploring strategic options for its AccuTOX® program. Further updates are expected as these initiatives develop.
Defence Therapeutics' corporate update provides context for readers following biotech developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 29, 2026 02:52 WIB: Of 100 priced US health-sector stocks tradable on Pluang, 52 rose and 47 fell today. Notable movers include TDOC (Teladoc Health Inc) at USD 5.88 with a 1-day change of -3.37% and a typical hold time of 39 days, TXG (10X Genomics Inc) at USD 88.15 with a 1-day change of +2.85%, a typical hold time of 92 days, and Pluang order activity split 49% Sell / 51% Buy, and CLPT (ClearPoint Neuro Inc) at USD 15.25 with a 1-day change of +2.83%, a typical hold time of 10 days, and Pluang order activity 0% Sell / 100% Buy.
Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...
Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...
Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...
A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...
Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...
